Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Cerebral Cavernous Malformation (CCM) is a cerebrovascular disease which can be either
congenital in origin or sporadic and is characterized by the presence of isolated or multiple
CCM lesions, causing recurrent headache, seizures, focal neurological deficits and
hemorrhages. Inasmuch, to date, the only curative treatment available is limited to surgical
lesion eradication or stereotactic radiosurgery. It is therefore necessary to find an
effective medical treatment that may limit disease progression and decrease the burden of
adverse clinical events. The non-selective betablocker propranolol has been found to be
effective in the treatment of infantile cutaneous hemangioma, and anecdotal reports have been
published on its efficacy in CCM. The safety profile of propranolol has been documented in
millions of patients of all ages.
The primary objective of this exploratory trial is to test whether a chronic treatment with
propranolol will reduce the burden of cerebrovascular lesions, of clinical events and
symptoms in patients with familial CCM.
Phase:
Phase 2
Details
Lead Sponsor:
Mario Negri Institute for Pharmacological Research